Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAGrttnews·Aug 14 at 03:26 AMPARK-4.94%AVAH+1.46%
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst UpgradeMarket Beat·Aug 12 at 11:20 AMCOAG+1.99%
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC WainwrightMarket Beat·Aug 11 at 11:42 AMCOAG+1.99%
Hemab Q2 FY26 net loss widens to $24.15 million; R&D expenses rise to $20.34 millionPUBT·Aug 11 at 06:03 AMCOAG+1.99%
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIXrttnews·Aug 7 at 05:33 AMMNPR-2.85%ANRO+0.09%
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRSrttnews·Jul 21 at 02:45 AMMNPR-2.85%SOPH+3.84%
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8% - Should You Sell?Market Beat·Jul 15 at 11:22 AMCOAG+1.99%
Biotech Stocks At 52-Week Highs - COAG, ALMR, PGNY, TXG, VMDrttnews·Jul 14 at 03:05 AMVMD+3.27%PGNY-1.19%
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress | COAG Stock NewsStockTitan·Jul 13 at 10:45 PMCOAG+1.99%
Hemab Therapeutics presents new clinical data from HMB-002 in VWDbusinessinsider·Jul 12 at 03:00 PMCOAG+1.99%
